{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:10:21Z","timestamp":1791655821818,"version":"4.3.4"},"reference-count":256,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["SAF2017-89672-R"],"award-info":[{"award-number":["SAF2017-89672-R"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC), the most common malignancy of the pancreas, shows a dismal and grim overall prognosis and survival rate, which have remained virtually unchanged for over half a century. PDAC is the most lethal of all cancers, with the highest mortality-to-incidence ratio. PDAC responds poorly to current therapies and remains an incurable malignancy. Therefore, novel therapeutic targets and drugs are urgently needed for pancreatic cancer treatment. Selective induction of apoptosis in cancer cells is an appealing approach in cancer therapy. Apoptotic cell death is highly regulated by different signaling routes that involve a variety of subcellular organelles. Endoplasmic reticulum (ER) stress acts as a double-edged sword at the interface of cell survival and death. Pancreatic cells exhibit high hormone and enzyme secretory functions, and thereby show a highly developed ER. Thus, pancreatic cancer cells display a prominent ER. Solid tumors have to cope with adverse situations in which hypoxia, lack of certain nutrients, and the action of certain antitumor agents lead to a complex interplay and crosstalk between ER stress and autophagy\u2014the latter acting as an adaptive survival response. ER stress also mediates cell death induced by a number of anticancer drugs and experimental conditions, highlighting the pivotal role of ER stress in modulating cell fate. The alkylphospholipid analog prototype edelfosine is selectively taken up by tumor cells, accumulates in the ER of a number of human solid tumor cells\u2014including pancreatic cancer cells\u2014and promotes apoptosis through a persistent ER-stress-mediated mechanism both in vitro and in vivo. Here, we discuss and propose that direct ER targeting may be a promising approach in the therapy of pancreatic cancer, opening up a new avenue for the treatment of this currently incurable and deadly cancer. Furthermore, because autophagy acts as a cytoprotective response to ER stress, potentiation of the triggering of a persistent ER response by combination therapy, together with the use of autophagy blockers, could improve the current gloomy expectations for finding a cure for this type of cancer.<\/jats:p>","DOI":"10.3390\/cancers13164173","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T09:58:06Z","timestamp":1629367086000},"page":"4173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-2434","authenticated-orcid":false,"given":"Faustino","family":"Mollinedo","sequence":"first","affiliation":[{"name":"Centro de Investigaciones Biol\u00f3gicas Margarita Salas, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, C\/Ramiro de Maeztu 9, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Gajate","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Biol\u00f3gicas Margarita Salas, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Laboratory of Cell Death and Cancer Therapy, Department of Molecular Biomedicine, C\/Ramiro de Maeztu 9, E-28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"ref_1","unstructured":"Talathi, S.S., Zimmerman, R., and Young, M. (2021, June 15). Anatomy, Abdomen and Pelvis, Pancreas, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532912\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators","volume":"4","author":"Sohn","year":"2000","journal-title":"J. Gastrointest. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13651820802291233","article-title":"The anatomic location of pancreatic cancer is a prognostic factor for survival","volume":"10","author":"Artinyan","year":"2008","journal-title":"HPB (Oxford)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17196","DOI":"10.3748\/wjg.v20.i45.17196","article-title":"Relationship between the exocrine and endocrine pancreas after acute pancreatitis","volume":"20","author":"Das","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpg.2007.10.017","article-title":"New advances in pancreatic cell physiology and pathophysiology","volume":"22","author":"Weiss","year":"2008","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1172\/JCI57131","article-title":"Pancreatic ductal cells in development, regeneration, and neoplasia","volume":"121","author":"Reichert","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pelosi, E., Castelli, G., and Testa, U. (2017). Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines, 5.","DOI":"10.3390\/biomedicines5040065"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrgastro.2017.12","article-title":"Acinar cell plasticity and development of pancreatic ductal adenocarcinoma","volume":"14","author":"Storz","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.12688\/f1000research.10188.1","article-title":"Pancreatic neuroendocrine tumors: The basics, the gray zone, and the target","volume":"6","author":"Kelgiorgi","year":"2017","journal-title":"F1000Res"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-011-0172-2","article-title":"Neuroendocrine pancreatic tumors: Guidelines for management and update","volume":"13","author":"Burns","year":"2012","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1148\/rg.2020200025","article-title":"Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification","volume":"40","author":"Khanna","year":"2020","journal-title":"Radiographics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clinre.2018.08.005","article-title":"Life expectancy in pancreatic neuroendocrine cancer","volume":"43","author":"Brooks","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_14","first-page":"725","article-title":"Surgical management of pancreatic cancer","volume":"16","author":"Ahrendt","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2476","DOI":"10.1136\/bmj.e2476","article-title":"Pancreatic adenocarcinoma","volume":"344","author":"Banga","year":"2012","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_20","unstructured":"International Agency for Research on Cancer, WHO (2021, June 15). Very high HDI. The Global Cancer Observatory. Globocan 2020. WHO. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/981-very-high-hdi-fact-sheets.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/ijc.30382","article-title":"A global view on cancer incidence and national levels of the human development index","volume":"139","author":"Fidler","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_23","unstructured":"International Agency for Research on Cancer, WHO (2021, June 15). Low HDI. The Global Cancer Observatory. Globocan 2020. WHO. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/984-low-hdi-fact-sheets.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2174\/1381612826666200713170047","article-title":"Epidemiology of the Incidence and Mortality of Pancreas Cancer and its Relationship with the Human Development Index (HDI) in the World: An Ecological Study in 2018","volume":"26","author":"Goodarzi","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.puhe.2017.12.015","article-title":"Global incidence and mortality rates in pancreatic cancer and the association with the Human Development Index: Decomposition approach","volume":"156","author":"Veisani","year":"2018","journal-title":"Public Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1038\/s41598-017-02997-2","article-title":"Global temporal patterns of pancreatic cancer and association with socioeconomic development","volume":"7","author":"Wong","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3961\/jpmph.19.100","article-title":"The Relationship Between Obesity, Overweight, and the Human Development Index in World Health Organization Eastern Mediterranean Region Countries","volume":"53","author":"Ataey","year":"2020","journal-title":"J. Prev. Med. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1470-2045(14)71123-4","article-title":"Global burden of cancer attributable to high body-mass index in 2012: A population-based study","volume":"16","author":"Arnold","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"188326","DOI":"10.1016\/j.bbcan.2019.188326","article-title":"The intricate relationship between diabetes, obesity and pancreatic cancer","volume":"1873","author":"Paternoster","year":"2020","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"ref_30","unstructured":"International Agency for Research on Cancer, WHO (2021, June 15). World. The Global Cancer Observatory. Globocan 2020. WHO. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1080\/0284186X.2016.1197419","article-title":"More deaths from pancreatic cancer than breast cancer in the EU by 2017","volume":"55","author":"Ferlay","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1634\/theoncologist.2014-0408","article-title":"Allelic ratio of KRAS mutations in pancreatic cancer","volume":"20","author":"Lennerz","year":"2015","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","article-title":"ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup","volume":"9","author":"Chan","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.3748\/wjg.v20.i31.10740","article-title":"Borderline resectable pancreatic cancer: Definitions and management","volume":"20","author":"Lopez","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11210","DOI":"10.3748\/wjg.v20.i32.11210","article-title":"Selection criteria in resectable pancreatic cancer: A biological and morphological approach","volume":"20","author":"Tamburrino","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.14701\/ahbps.2018.22.4.386","article-title":"Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data","volume":"22","author":"Lee","year":"2018","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1245\/s10434-009-0670-7","article-title":"Resectable pancreatic cancer: Who really benefits from resection?","volume":"16","author":"Barugola","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/EDBK_200861","article-title":"What Makes a Pancreatic Cancer Resectable?","volume":"38","author":"Evans","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1758835919875568","DOI":"10.1177\/1758835919875568","article-title":"An update on treatment options for pancreatic adenocarcinoma","volume":"11","author":"Lambert","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.surg.2015.09.018","article-title":"Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy","volume":"159","author":"Christians","year":"2016","journal-title":"Surgery"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.pan.2016.02.005","article-title":"A comprehensive analysis on expected years of life lost due to pancreatic cancer","volume":"16","author":"Cucchetti","year":"2016","journal-title":"Pancreatology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Huang, L., Jansen, L., Balavarca, Y., Babaei, M., van der Geest, L., Lemmens, V., Van Eycken, L., De Schutter, H., Johannesen, T.B., and Primic-Zakelj, M. (2018). Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: A large, international population-based study. BMC Med., 16.","DOI":"10.1186\/s12916-018-1120-9"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mc.20785","article-title":"Pancreatic cancer: Overview of descriptive epidemiology","volume":"51","author":"Bosetti","year":"2012","journal-title":"Mol. Carcinog."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X13478680","article-title":"Pancreatic cancer: Why is it so hard to treat?","volume":"6","author":"Oberstein","year":"2013","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000151536","article-title":"Biological approaches to therapy of pancreatic cancer","volume":"8","author":"Wong","year":"2008","journal-title":"Pancreatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archsurg.2011.2281","article-title":"Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer","volume":"147","author":"Katz","year":"2012","journal-title":"Arch. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.pathmechdis.3.121806.154305","article-title":"Pancreatic cancer","volume":"3","author":"Maitra","year":"2008","journal-title":"Annu. Rev. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Adamska, A., Domenichini, A., and Falasca, M. (2017). Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071338"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: Know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/medicina54030048","article-title":"Chemotherapy in Pancreatic Cancer: A Systematic Review","volume":"54","author":"Hajatdoost","year":"2018","journal-title":"Medicina (Kaunas)"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrclinonc.2009.236","article-title":"Advanced pancreatic carcinoma: Current treatment and future challenges","volume":"7","author":"Stathis","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/bjc.2016.406","article-title":"Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre","volume":"116","author":"Faluyi","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.53","article-title":"Pancreatic cancer: From state-of-the-art treatments to promising novel therapies","volume":"12","author":"Hidalgo","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.21037\/tgh.2019.06.09","article-title":"Palliative chemotherapy in pancreatic cancer-treatment sequences","volume":"4","author":"Abbassi","year":"2019","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"576399","DOI":"10.3389\/fonc.2020.576399","article-title":"Stroma-Targeting Therapy in Pancreatic Cancer: One Coin with Two Sides?","volume":"10","author":"Jiang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure\u2013an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MPA.0000000000001023","article-title":"Stroma\u2013A Double-Edged Sword in Pancreatic Cancer: A Lesson from Targeting Stroma in Pancreatic Cancer with Hedgehog Signaling Inhibitors","volume":"47","author":"Gu","year":"2018","journal-title":"Pancreas"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2016.12.035","article-title":"Pancreatic cancer: Stroma and its current and emerging targeted therapies","volume":"391","author":"Kota","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/MPA.0000000000000753","article-title":"Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer?","volume":"46","author":"Thota","year":"2017","journal-title":"Pancreas"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_67","first-page":"70","article-title":"Treatment of metastatic pancreatic adenocarcinoma: A review","volume":"28","author":"Thota","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19281","DOI":"10.1038\/s41598-020-76465-9","article-title":"Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer","volume":"10","author":"Roviello","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_70","first-page":"23","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Desseigne","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1756283X17713879","article-title":"Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions","volume":"10","author":"Lambert","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sawada, M., Kasuga, A., Mie, T., Furukawa, T., Taniguchi, T., Fukuda, K., Yamada, Y., Takeda, T., Kanata, R., and Matsuyama, M. (2020). Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06945-8"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.2147\/OTT.S200754","article-title":"Modified FOLFIRINOX for unresectable locally advanced\/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience","volume":"12","author":"Cavanna","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: A systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_75","first-page":"27","article-title":"Biomarkers and Targeted Therapy in Pancreatic Cancer","volume":"8","author":"Karandish","year":"2016","journal-title":"Biomark. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1245\/s10434-015-4463-x","article-title":"Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer","volume":"23","author":"Tanaka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Amanam, I., and Chung, V. (2018). Targeted Therapies for Pancreatic Cancer. Cancers (Basel), 10.","DOI":"10.3390\/cancers10020036"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-4598-2-15","article-title":"Genetic alterations in pancreatic carcinoma","volume":"2","author":"Schneider","year":"2003","journal-title":"Mol. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/gm430","article-title":"Pancreatic cancer genomics: Insights and opportunities for clinical translation","volume":"5","author":"Brosnan","year":"2013","journal-title":"Genome Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Nelson, S.R., and Walsh, N. (2020). Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. Cancers (Basel), 12.","DOI":"10.3390\/cancers12051233"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.21037\/atm.2019.06.40","article-title":"Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF-->MEK-->ERK signaling and autophagy survival response","volume":"7","author":"Mollinedo","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/ijc.31603","article-title":"Phase I\/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer","volume":"143","author":"Hidalgo","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-019-0367-9","article-title":"Protective autophagy elicited by RAF-->MEK-->ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10396-014-0576-2","article-title":"Evolution of pancreas in aging: Degenerative variation or early changes of disease?","volume":"42","author":"Chantarojanasiri","year":"2015","journal-title":"J. Med. Ultrason."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/agm2.12095","article-title":"Pancreatic senescence and its clinical manifestations","volume":"3","author":"Wang","year":"2020","journal-title":"Aging Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00276-012-0988-x","article-title":"Age-related volumetric changes in pancreas: A stereological study on computed tomography","volume":"34","author":"Caglar","year":"2012","journal-title":"Surg. Radiol. Anat."},{"key":"ref_93","first-page":"253","article-title":"Effect of aging and diffuse chronic pancreatitis on pancreas elasticity evaluated using semiquantitative EUS elastography","volume":"35","author":"Janssen","year":"2014","journal-title":"Ultraschall Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.ejrad.2011.07.014","article-title":"Age-related changes in normal adult pancreas: MR imaging evaluation","volume":"81","author":"Sato","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00428-005-0032-1","article-title":"Pancreatic fibrosis associated with age and ductal papillary hyperplasia","volume":"447","author":"Detlefsen","year":"2005","journal-title":"Virchows Arch."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"127","DOI":"10.32604\/biocell.2004.28.127","article-title":"Histomorphological and quantitative immunohistochemical changes in the rat pancreas during aging","volume":"28","author":"Riccillo","year":"2004","journal-title":"Biocell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/joim.12745","article-title":"The ageing pancreas: A systematic review of the evidence and analysis of the consequences","volume":"283","author":"Lohr","year":"2018","journal-title":"J. Intern. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1038\/s41598-020-64068-3","article-title":"Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: A population-based retrospective study","volume":"10","author":"Wang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.biocel.2005.12.001","article-title":"Pancreatic acinar cell: Its role in acute pancreatitis","volume":"38","author":"Leung","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1469-185X.1978.tb01437.x","article-title":"Synthesis, intracellular transport and discharge of exportable proteins in the pancreatic acinar cell and other cells","volume":"53","author":"Case","year":"1978","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.0510790103","article-title":"The unique cytoarchitecture of human pancreatic islets has implications for islet cell function","volume":"103","author":"Cabrera","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Da Silva Xavier, G. (2018). The Cells of the Islets of Langerhans. J. Clin. Med., 7.","DOI":"10.3390\/jcm7030054"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1023\/A:1016175429877","article-title":"Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells","volume":"7","author":"Oyadomari","year":"2002","journal-title":"Apoptosis"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2017.00078","article-title":"Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate","volume":"7","author":"Corazzari","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Robinson, C.M., Talty, A., Logue, S.E., Mnich, K., Gorman, A.M., and Samali, A. (2021). An Emerging Role for the Unfolded Protein Response in Pancreatic Cancer. Cancers (Basel), 13.","DOI":"10.3390\/cancers13020261"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1093\/emboj\/17.19.5708","article-title":"Cloning of mammalian Ire1 reveals diversity in the ER stress responses","volume":"17","author":"Wang","year":"1998","journal-title":"EMBO J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1242\/jcs.02731","article-title":"ER stress disrupts Ca2+-signaling complexes and Ca2+ regulation in secretory and muscle cells from PERK-knockout mice","volume":"119","author":"Huang","year":"2006","journal-title":"J. Cell Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1091\/mbc.10.11.3787","article-title":"Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress","volume":"10","author":"Haze","year":"1999","journal-title":"Mol. Biol. Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"eaao4908","DOI":"10.1126\/science.aao4908","article-title":"Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases","volume":"360","author":"Pommier","year":"2018","journal-title":"Science"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"27551","DOI":"10.1074\/jbc.M113.528174","article-title":"Endoplasmic reticulum stress is chronically activated in chronic pancreatitis","volume":"289","author":"Sah","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fonc.2017.00028","article-title":"Molecular Pathways Controlling Autophagy in Pancreatic Cancer","volume":"7","author":"New","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4161\/auto.21315","article-title":"Depletion of L-arginine induces autophagy as a cytoprotective response to endoplasmic reticulum stress in human T lymphocytes","volume":"8","author":"Munder","year":"2012","journal-title":"Autophagy"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Garcia-Carbonero, N., Li, W., Cabeza-Morales, M., Martinez-Useros, J., and Garcia-Foncillas, J. (2018). New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092468"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1158\/0008-5472.CAN-05-2394","article-title":"Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-018-0145-3","article-title":"Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma","volume":"119","author":"Xu","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1074\/jbc.M210284200","article-title":"Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling","volume":"278","author":"Mandic","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1158\/0008-5472.CAN-06-0169","article-title":"Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes","volume":"66","author":"Carracedo","year":"2006","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Limonta, P., Moretti, R.M., Marzagalli, M., Fontana, F., Raimondi, M., and Montagnani Marelli, M. (2019). Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040961"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"11658","DOI":"10.1158\/0008-5472.CAN-05-2370","article-title":"Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis","volume":"65","author":"Nawrocki","year":"2005","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1038\/oncsis.2017.72","article-title":"Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers","volume":"6","author":"Avril","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1002\/cti2.1007","article-title":"Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance","volume":"7","author":"Nikesitch","year":"2018","journal-title":"Clin. Transl. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nature02262","article-title":"Quality control in the endoplasmic reticulum protein factory","volume":"426","author":"Sitia","year":"2003","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrm1052","article-title":"Quality control in the endoplasmic reticulum","volume":"4","author":"Ellgaard","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The unfolded protein response: From stress pathway to homeostatic regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/febs.13598","article-title":"Cell death induced by endoplasmic reticulum stress","volume":"283","author":"Iurlaro","year":"2016","journal-title":"FEBS J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1038\/sj.onc.1207108","article-title":"Regulation of apoptosis by endoplasmic reticulum pathways","volume":"22","author":"Breckenridge","year":"2003","journal-title":"Oncogene"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1083\/jcb.200310015","article-title":"Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death","volume":"165","author":"Hitomi","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1242\/jcs.035832","article-title":"The UPR and cell fate at a glance","volume":"123","author":"Merksamer","year":"2010","journal-title":"J. Cell Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1038\/onc.2011.446","article-title":"Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum","volume":"31","author":"Gajate","year":"2012","journal-title":"Oncogene"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: Controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1016\/j.bbamcr.2013.06.028","article-title":"ER stress-induced cell death mechanisms","volume":"1833","author":"Sano","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"14596","DOI":"10.18632\/oncotarget.4053","article-title":"Endoplasmic reticulum targeting in Ewing\u2019s sarcoma by the alkylphospholipid analog edelfosine","volume":"6","author":"Bonilla","year":"2015","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","article-title":"The Unfolded Protein Response and Cell Fate Control","volume":"69","author":"Hetz","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0968-0004(01)01908-9","article-title":"The glucose-regulated proteins: Stress induction and clinical applications","volume":"26","author":"Lee","year":"2001","journal-title":"Trends Biochem. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"44723","DOI":"10.1038\/srep44723","article-title":"The Endoplasmic Reticulum Chaperone GRP78\/BiP Modulates Prion Propagation in vitro and in vivo","volume":"7","author":"Park","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1038\/cddis.2015.183","article-title":"Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate","volume":"6","author":"Liu","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1083\/jcb.200212059","article-title":"Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol","volume":"160","author":"Breckenridge","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/emboj.2010.346","article-title":"Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction","volume":"30","author":"Iwasawa","year":"2011","journal-title":"EMBO J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1167\/iovs.09-3628","article-title":"Dual involvement of caspase-4 in inflammatory and ER stress-induced apoptotic responses in human retinal pigment epithelial cells","volume":"50","author":"Bian","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.molcel.2008.02.011","article-title":"Increased mTORC1 signaling UPRegulates stress","volume":"29","author":"Reiling","year":"2008","journal-title":"Mol. Cell"},{"key":"ref_144","first-page":"266","article-title":"Endoplasmic reticulum stress and pancreatic beta-cell death","volume":"22","author":"Fonseca","year":"2011","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.molmet.2019.06.012","article-title":"Endoplasmic reticulum stress, degeneration of pancreatic islet beta-cells, and therapeutic modulation of the unfolded protein response in diabetes","volume":"27S","author":"Ghosh","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/1389200023337225","article-title":"Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (Edelfosine), a proapoptotic agent in tumor cells","volume":"3","author":"Gajate","year":"2002","journal-title":"Curr. Drug Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2174\/0929867043363703","article-title":"ET-18-OCH3 (edelfosine): A selective antitumour lipid targeting apoptosis through intracellular activation of Fas\/CD95 death receptor","volume":"11","author":"Mollinedo","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/13543776.17.4.385","article-title":"Antitumor ether lipids: Proapoptotic agents with multiple therapeutic indications","volume":"17","author":"Mollinedo","year":"2007","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2174\/1871520614999140313160011","article-title":"Antitumor alkylphospholipid analogs: A promising and growing family of synthetic cell membrane-targeting molecules for cancer treatment","volume":"14","author":"Mollinedo","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1871520614666140309222259","article-title":"Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine","volume":"14","author":"Gajate","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_151","first-page":"345","article-title":"Visceral leishmaniasis\u2013current therapeutic modalities","volume":"123","author":"Sundar","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1517\/14656566.6.16.2821","article-title":"Treatment of visceral leishmaniasis","volume":"6","author":"Sundar","year":"2005","journal-title":"Expert Opin. Pharm."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1078-0432.CCR-09-1837","article-title":"Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed\/refractory Waldenstrom\u2019s macroglobulinemia","volume":"16","author":"Ghobrial","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1200\/JCO.2010.33.9788","article-title":"Perifosine plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I\/II trial","volume":"29","author":"Richardson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2141.2012.09173.x","article-title":"Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed\/refractory multiple myeloma: A Phase I Multiple Myeloma Research Consortium study","volume":"158","author":"Jakubowiak","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425255.2012.681376","article-title":"Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: Mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity","volume":"8","author":"Richardson","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood.v122.21.3189.3189","article-title":"Randomized Placebo-Controlled Phase III Study of Perifosine Combined with Bortezomib and Dexamethasone in Relapsed, Refractory Multiple Myeloma Patients Previously Treated with Bortezomib","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3109\/10428194.2013.824080","article-title":"Perifosine treatment in chronic lymphocytic leukemia: Results of a phase II clinical trial and in vitro studies","volume":"55","author":"Friedman","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2011.36.1980","article-title":"Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer","volume":"29","author":"Bendell","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Becher, O.J., Millard, N.E., Modak, S., Kushner, B.H., Haque, S., Spasojevic, I., Trippett, T.M., Gilheeney, S.W., Khakoo, Y., and Lyden, D.C. (2017). A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178593"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e26409","DOI":"10.1002\/pbc.26409","article-title":"A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors","volume":"64","author":"Becher","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ijc.30440","article-title":"A phase I\/Ib trial targeting the PI3K\/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma","volume":"140","author":"Kushner","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-017-0504-6","article-title":"Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations","volume":"35","author":"Hasegawa","year":"2017","journal-title":"Invest. New Drugs"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-019-03243-7","article-title":"Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma","volume":"144","author":"Kaley","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/acn3.51009","article-title":"Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma","volume":"7","author":"Kaley","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2001.19.21.4150","article-title":"Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer","volume":"19","author":"Leonard","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2006-04-016824","article-title":"Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts","volume":"109","author":"Gajate","year":"2007","journal-title":"Blood"},{"key":"ref_171","unstructured":"Kny, G. (1969). \u00dcber Lysolecithin-Analoga\u2013Synthese und biologische Eigenschaften. [Diploma Thesis, University of Freiburg]."},{"key":"ref_172","first-page":"1320","article-title":"Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): Molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL","volume":"57","author":"Mollinedo","year":"1997","journal-title":"Cancer Res."},{"key":"ref_173","first-page":"5803","article-title":"Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells","volume":"46","author":"Hoffman","year":"1986","journal-title":"Cancer Res."},{"key":"ref_174","first-page":"113","article-title":"Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver","volume":"23","author":"Magistrelli","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Varela-M, R.E., Villa-Pulgarin, J.A., Yepes, E., Muller, I., Modolell, M., Munoz, D.L., Robledo, S.M., Muskus, C.E., Lopez-Aban, J., and Muro, A. (2012). In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant Parasites. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001612"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Villa-Pulgarin, J.A., Gajate, C., Botet, J., Jimenez, A., Justies, N., Varela-M, R.E., Cuesta-Marban, A., Muller, I., Modolell, M., and Revuelta, J.L. (2017). Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005805"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Yepes, E., Varela-M, R.E., Lopez-Aban, J., Dakir, E.H., Mollinedo, F., and Muro, A. (2014). In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109431"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Yepes, E., Varela-M, R.E., Lopez-Aban, J., Rojas-Caraballo, J., Muro, A., and Mollinedo, F. (2015). Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003893"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.actatropica.2016.07.001","article-title":"The alkylphospholipid edelfosine shows activity against Strongyloides venezuelensis and induces apoptosis-like cell death","volume":"162","author":"Ruano","year":"2016","journal-title":"Acta. Trop."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1158\/1078-0432.CCR-09-2456","article-title":"In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts","volume":"16","author":"Mollinedo","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1038\/onc.2010.131","article-title":"Lipid raft-targeted therapy in multiple myeloma","volume":"29","author":"Mollinedo","year":"2010","journal-title":"Oncogene"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1038\/onc.2009.183","article-title":"Involvement of mitochondria and recruitment of Fas\/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions","volume":"28","author":"Gajate","year":"2009","journal-title":"Oncogene"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/jpet.108.148254","article-title":"Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis","volume":"329","author":"Mollinedo","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.20040213","article-title":"Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis","volume":"200","author":"Gajate","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z","article-title":"Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis","volume":"85","author":"Gajate","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood.V98.13.3860","article-title":"The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas\/CD95 into membrane rafts in human leukemic cells","volume":"98","author":"Gajate","year":"2001","journal-title":"Blood"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drup.2006.04.002","article-title":"Fas\/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy","volume":"9","author":"Mollinedo","year":"2006","journal-title":"Drug Resist. Updat."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Gajate, C., Gonzalez-Camacho, F., and Mollinedo, F. (2009). Involvement of raft aggregates enriched in Fas\/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005044"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jbior.2014.10.003","article-title":"Lipid rafts as major platforms for signaling regulation in cancer","volume":"57","author":"Mollinedo","year":"2015","journal-title":"Adv. Biol. Regul."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10495-015-1104-6","article-title":"Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling","volume":"20","author":"Gajate","year":"2015","journal-title":"Apoptosis"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1189\/jlb.2MR0215-055R","article-title":"Lipid raft-mediated Fas\/CD95 apoptotic signaling in leukemic cells and normal leukocytes and therapeutic implications","volume":"98","author":"Gajate","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Micheau, O. (2017). Fas\/CD95, lipid rafts and cancer. TRAIL, Fas Ligand, TNF and TLR3 in Cancer, Springer International Publishing AG.","DOI":"10.1007\/978-3-319-56805-8"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1194\/jlr.TR119000439","article-title":"Lipid rafts as signaling hubs in cancer cell survival\/death and invasion: Implications in tumor progression and therapy","volume":"61","author":"Mollinedo","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbrc.2009.01.147","article-title":"Lipid raft connection between extrinsic and intrinsic apoptotic pathways","volume":"380","author":"Gajate","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fon.10.34","article-title":"Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy","volume":"6","author":"Mollinedo","year":"2010","journal-title":"Future Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fon.10.22","article-title":"Lipid rafts, death receptors and CASMERs: New insights for cancer therapy","volume":"6","author":"Mollinedo","year":"2010","journal-title":"Future Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"38047","DOI":"10.1074\/jbc.M502849200","article-title":"Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition","volume":"280","author":"Zaremberg","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1038\/bcj.2013.15","article-title":"Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma","volume":"3","author":"Roue","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1074\/jbc.M112.425744","article-title":"Alteration of plasma membrane organization by an anticancer lysophosphatidylcholine analogue induces intracellular acidification and internalization of plasma membrane transporters in yeast","volume":"288","author":"Czyz","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"8405","DOI":"10.1074\/jbc.M112.425769","article-title":"Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast","volume":"288","author":"Botet","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"14833","DOI":"10.1074\/jbc.M511251200","article-title":"Differential Targets and Subcellular Localization of Antitumor Alkyl-lysophospholipid in Leukemic Versus Solid Tumor Cells","volume":"281","author":"Gajate","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_202","unstructured":"Lonial, S. (2008). Death receptors in multiple myeloma and therapeutic opportunities. Myeloma Therapy. Pursuing the Plasma Cell, Humana Press."},{"key":"ref_203","first-page":"109","article-title":"The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: A double-edged sword of adaptation and apoptosis","volume":"4","author":"Hua","year":"2013","journal-title":"Front. Genet."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1210\/en.2005-1494","article-title":"Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis","volume":"147","author":"Karaskov","year":"2006","journal-title":"Endocrinology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1074\/jbc.M607627200","article-title":"Selective inhibition of eukaryotic translation initiation factor 2 alpha dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic beta-cell dysfunction and apoptosis","volume":"282","author":"Cnop","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1242\/jcs.026062","article-title":"Initiation and execution of lipotoxic ER stress in pancreatic beta-cells","volume":"121","author":"Cunha","year":"2008","journal-title":"J. Cell Sci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1021\/jm049808a","article-title":"Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells","volume":"47","author":"Quesada","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1039\/C5CS00030K","article-title":"BODIPY-based probes for the fluorescence imaging of biomolecules in living cells","volume":"44","author":"Kowada","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fchem.2020.00290","article-title":"Editorial: BODIPYs and Their Derivatives: The Past, Present and Future","volume":"8","author":"Lu","year":"2020","journal-title":"Front. Chem."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1038\/cddis.2011.41","article-title":"Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria","volume":"2","author":"Mollinedo","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.200408169","article-title":"Bcl-XL specifically activates Bak to induce swelling and restructuring of the endoplasmic reticulum","volume":"168","author":"Klee","year":"2005","journal-title":"J. Cell Biol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1745-7254.2007.00568.x","article-title":"Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells","volume":"28","author":"Zhang","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fonc.2012.00140","article-title":"Lipid raft involvement in yeast cell growth and death","volume":"2","author":"Mollinedo","year":"2012","journal-title":"Front. Oncol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnins.2017.00177","article-title":"GRP78 at the Centre of the Stage in Cancer and Neuroprotection","volume":"11","author":"Casas","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/CIRCRESAHA.117.312641","article-title":"Endoplasmic Reticulum Chaperone GRP78 Protects Heart from Ischemia\/Reperfusion Injury through Akt Activation","volume":"122","author":"Bi","year":"2018","journal-title":"Circ. Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"10368","DOI":"10.1158\/0008-5472.CAN-07-0278","article-title":"Endoplasmic Reticulum Stress in the Proapoptotic Action of Edelfosine in Solid Tumor Cells","volume":"67","author":"Fonteriz","year":"2007","journal-title":"Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1089\/ars.2009.2485","article-title":"Role of the unfolded protein response regulator GRP78\/BiP in development, cancer, and neurological disorders","volume":"11","author":"Wang","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/mol.53.4.602","article-title":"Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine","volume":"53","author":"Gajate","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1073\/pnas.251194298","article-title":"SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase","volume":"98","author":"Bennett","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1101\/gad.992302","article-title":"ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats","volume":"16","author":"Nishitoh","year":"2002","journal-title":"Genes Dev."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/sj.onc.1210816","article-title":"Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy","volume":"27","author":"Gajate","year":"2008","journal-title":"Oncogene"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejmech.2018.02.086","article-title":"Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells","volume":"150","author":"Bello","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1128\/MCB.20.18.6731-6740.2000","article-title":"Caspase-resistant BAP31 inhibits fas-mediated apoptotic membrane fragmentation and release of cytochrome c from mitochondria","volume":"20","author":"Nguyen","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/S0021-9258(19)39106-9","article-title":"Phospholipid synthesis in a membrane fraction associated with mitochondria","volume":"265","author":"Vance","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1089\/ars.2014.6223","article-title":"Mitochondria-associated membranes: Composition, molecular mechanisms, and physiopathological implications","volume":"22","author":"Giorgi","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41419-017-0027-2","article-title":"Mitochondria-associated membranes (MAMs) and inflammation","volume":"9","author":"Missiroli","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbrc.2011.12.022","article-title":"The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria","volume":"417","author":"Fujimoto","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Mollinedo, F., and Gajate, C. (2021). Mitochondrial Targeting Involving Cholesterol-Rich Lipid Rafts in the Mechanism of Action of the Antitumor Ether Lipid and Alkylphospholipid Analog Edelfosine. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050763"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"a013235","DOI":"10.1101\/cshperspect.a013235","article-title":"Lipid transport between the endoplasmic reticulum and mitochondria","volume":"5","author":"Flis","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbamcr.2016.12.024","article-title":"Endoplasmic reticulum-mitochondria Ca2+ crosstalk in the control of the tumor cell fate","volume":"1864","author":"Missiroli","year":"2017","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12154-008-0009-z","article-title":"Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug","volume":"1","author":"Busto","year":"2008","journal-title":"J. Chem. Biol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1021\/acs.langmuir.8b01539","article-title":"Anticancer Agent Edelfosine Exhibits a High Affinity for Cholesterol and Disorganizes Liquid-Ordered Membrane Structures","volume":"34","author":"Ausili","year":"2018","journal-title":"Langmuir"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1021\/jp802165n","article-title":"Edelfosine Is Incorporated into Rafts and Alters Their Organization","volume":"112","author":"Ausili","year":"2008","journal-title":"J. Phys. Chem. B"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2004-07-2521","article-title":"Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity","volume":"105","author":"Munder","year":"2005","journal-title":"Blood"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2006-11-010389","article-title":"Suppression of T-cell functions by human granulocyte arginase","volume":"108","author":"Munder","year":"2006","journal-title":"Blood"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.it.2019.01.006","article-title":"Neutrophil Degranulation, Plasticity, and Cancer Metastasis","volume":"40","author":"Mollinedo","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.semcancer.2005.04.002","article-title":"Arginine deprivation and metabolomics: Important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells","volume":"15","author":"Wheatley","year":"2005","journal-title":"Semin. Cancer Biol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1022451705701","article-title":"Arginine deprivation and tumour cell death: Arginase and its inhibition","volume":"244","author":"Wheatley","year":"2003","journal-title":"Mol. Cell Biochem."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1038\/s41598-021-91947-0","article-title":"Neutrophils drive endoplasmic reticulum stress-mediated apoptosis in cancer cells through arginase-1 release","volume":"11","author":"Gajate","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3389\/fimmu.2019.02155","article-title":"Neutrophil Heterogeneity in Cancer: From Biology to Therapies","volume":"10","author":"Lecot","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1128\/MCB.01453-06","article-title":"Autophagy is activated for cell survival after endoplasmic reticulum stress","volume":"26","author":"Ogata","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/sj.cdd.4402200","article-title":"Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium","volume":"14","author":"Jaattela","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4161\/auto.4600","article-title":"How to interpret LC3 immunoblotting","volume":"3","author":"Mizushima","year":"2007","journal-title":"Autophagy"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/modpathol.2011.113","article-title":"Tumor-infiltrating neutrophils in pancreatic neoplasia","volume":"24","author":"Reid","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","article-title":"CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma","volume":"4","author":"Chao","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Wu, L., Saxena, S., Awaji, M., and Singh, R.K. (2019). Tumor-Associated Neutrophils in Cancer: Going Pro. Cancers (Basel), 11.","DOI":"10.3390\/cancers11040564"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Huber, M., Brehm, C.U., Gress, T.M., Buchholz, M., Alashkar Alhamwe, B., von Strandmann, E.P., Slater, E.P., Bartsch, J.W., Bauer, C., and Lauth, M. (2020). The Immune Microenvironment in Pancreatic Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197307"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"e20190354","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cam4.3695","article-title":"Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma","volume":"10","author":"Naso","year":"2021","journal-title":"Cancer Med."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Charles Jacob, H.K., Charles Richard, J.L., Signorelli, R., Kashuv, T., Lavania, S., Vaish, U., Boopathy, R., Middleton, A., Boone, M.M., and Sundaram, R. (2021). Modulation of Early Neutrophil Granulation: The Circulating Tumor Cell-Extravesicular Connection in Pancreatic Ductal Adenocarcinoma. Cancers (Basel), 13.","DOI":"10.3390\/cancers13112727"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cmdc.202000752","article-title":"1,2,4-Oxadiazole topsentin analogs with antiproliferative activity against pancreatic cancer cells, targeting GSK3\u03b2 kinase","volume":"16","author":"Carbone","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"112088","DOI":"10.1016\/j.ejmech.2020.112088","article-title":"Imidazo [2,1-b][1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells","volume":"189","author":"Cascioferro","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.21873\/anticanres.13509","article-title":"Biological evaluation of the antiproliferative and anti-migratory activity of a series of 3-(6-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole derivatives against pancreatic cancer cells","volume":"39","author":"Cascioferro","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Cascioferro, S., Li Petri, G., Parrino, B., El Hassouni, B., Carbone, D., Arizza, V., Perricone, U., Padova, A., Funel, N., and Peters, G.J. (2020). 3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole derivatives as new anticancer agents in the treatment of pancreatic ductal adenocarcinoma. Molecules, 25.","DOI":"10.3390\/molecules25020329"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/4173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:47:30Z","timestamp":1760165250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/16\/4173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":256,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13164173"],"URL":"https:\/\/doi.org\/10.3390\/cancers13164173","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]}}}